Star Health Reports 21% YoY Profit Growth to 518 Cr; COR Improves by 170 bps in H1FY26 under IFRS
24% growth in fresh retail premiums Expense ratio improves to 29.7% from…
South Korea’s Leading Hair Loss Treatment Company, AESMED Co., Ltd., to Participate in Cosmoprof Asia Hong Kong 2025
AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL,…
JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltne
SHANGHAI, Oct. 21, 2025 /PRNewswire/ -- China's leading multi-brand beauty group JOY GROUP…
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving…
Indian Mobile Operators Help Online Businesses Combat Scams and Identity Theft Through New Federated Network Services, Supported by GSMA Open Gateway
New GSMA report shows more than half of Indian's have been scammed,…
Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being
Results from a real-world survey suggest that semaglutide for weight management (Wegovy®)…
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
September 11, 2025 09:00 ET | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
As Agentic AI Gains Traction, 86% of Enterprises Anticipate Heightened Risks, Yet Only 2% of Companies Meet Responsible AI Gold Standards
With 95% of enterprises facing incidents, Infosys research reveals wide gap between…